Organovo Holdings Inc: Actualités dans d'autres langues | | US68620A1043

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	31/05
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease	21/05
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)	14/05
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering	09/05
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	16/04
Organovo's fatty liver disease drug meets main goal in mid-stage study	15/04
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo: Fiscal Q3 Earnings Snapshot	08/02
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	25/01
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25/01
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	09/01
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo: Fiscal Q2 Earnings Snapshot	10/11
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Organovo Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	03/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

31/05	Organovo Holdings, Inc. annonce ses résultats pour l'exercice clos le 31 mars 2024	CI
15/04	Le médicament d'Organovo contre la stéatose hépatique atteint son objectif principal lors d'une étude de mi-parcours	RE

Autres langues Organovo Holdings Inc Nyse

Actions

US68620A1043

Autres langues

Filtres

Cours en clôture Nyse Autres places de cotation
- ^USD	-